A meta-analysis on the diagnostic performance of 18F-FDG and 11C-Methionine PET for differentiating brain tumors

American Journal of Neuroradiology

Volumn 35, Issue 6, 2014, Pages 1058-1065

  Zhao, C ^a   Zhang, Ying ^b   Wang, J ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; METHIONINE C 11; CARBON-11 METHIONINE; METHIONINE; RADIOPHARMACEUTICAL AGENT;

AREA UNDER THE CURVE; ARTICLE; BRAIN TUMOR; CANCER DIAGNOSIS; CANCER RECURRENCE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; MEDLINE; META ANALYSIS (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; QUALITY CONTROL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TUMOR DIFFERENTIATION; BRAIN NEOPLASMS; CLASSIFICATION; DIAGNOSTIC USE; DIFFERENTIAL DIAGNOSIS; DRUG EFFECTS; META ANALYSIS; PREVALENCE; PROCEDURES; REPRODUCIBILITY; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA;

BRAIN NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FLUORODEOXYGLUCOSE F18; HUMANS; METHIONINE; POSITRON-EMISSION TOMOGRAPHY; PREVALENCE; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 84902329936     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A3718     Document Type: Article

References (50)

1. Chen W, Silverman DH, Delaloye S, et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG-PET and evaluation of diagnostic accuracy. J Nucl Med 2006;47:904-11 (Pubitemid 46939941)
2. Ricci PE, Karis JP, Heiserman JE, et al. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? AJNR Am J Neuroradiol 1998;19:407-13 (Pubitemid 30422740)
3. Wong TZ, van der Westhuizen GJ, Coleman RE. Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am 2002;12:615-26 (Pubitemid 36015495)
4. Sasaki M, Kuwabara Y, Yoshida T, et al. A comparative study of thallium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours. Eur J Nucl Med 1998;25:1261-69 (Pubitemid 28446052)
5. Zuo C, Liu Y, Guan Y, et al. Clinical application of FDG-PET for the diagnosis of recurrent glioma. [in Chinese] Nuclear Techniques 2001;24:899-902
6. Gómez-Río M, Rodriguez-Fernandez A, Ramos-Font C, et al. Diagnostic accuracy of 201Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence. Eur J Nucl Med Mol Imaging 2008;35:966-75
7. Choi SJ, Kim JS, Kim JH, et al. [18F]3′-deoxy-3′- fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging 2005;32:653-59
8. Pauleit D, Stoffels G, Bachofner A, et al. Comparison of (18)F-FET and (18)F-FDG-PET in brain tumors. Nucl Med Biol 2009; 36:779 - 87
9. Lau EW, Drummond KJ, Ware RE, et al. Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour. J Clin Neurosci 2010;17:43-49
10. Estrada G, Gonzalez-Maya L, Celis-Lopez MA, et al. Diagnostic approach in suspected recurrent primary brain tumors using (18)FDG-PET/MRI, perfusion MRI, visual and quantitative analysis, and three dimensional stereotactic surface projections: first experience in Mexico. Rev Esp Med Nucl 2008;27:329-39
11. McCarthy M, Yuan JB, Campbell A, et al. 18F-fluorodeoxyglucose positron emission tomography imaging in brain tumours: the Western Australia positron emission tomography/cyclotron service experience. J Med Imaging Radiat Oncol 2008;52:564-69
12. Kahn D, Follett KA, Bushnell DL, et al. Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET. AJR Am J Roentgenol 1994;163:1459-65
13. Thompson TP, Lunsford LD, Kondziolka D. Distinguishing recurrent tumor and radiation necrosis with positron emission tomography versus stereotactic biopsy. Stereotact Funct Neurosurg 1999;73:9-14 (Pubitemid 30344992)
14. Sun A, Sun L, Wang R, et al. Value of 18F-FDG-PET in differentiation of brain tumor recurrence from radiation necrosis after radiotherapy. [in Chinese] Chin J Med Imaging Technol 2004;20:1484-86
15. Santra A, Kumar R, Sharma P, et al. 18F-FDG-PET-CT in patients with recurrent glioma: comparison with contrast enhanced MRI. Eur J Radiol 2012;81:508-13
16. Hong IK, Kim JH, Ra YS, et al. Diagnostic usefulness of 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography in recurrent brain tumor. J Comput Assist Tomogr 2011;35:679-84
17. Tan H, Chen L, Guan Y, et al. Comparison of MRI, 18F-FDG, and 11C-choline PET/CT for their potentials in differentiating brain tumor recurrence from brain tumor necrosis following radiotherapy. Clin Nucl Med 2011;36:978-81
18. Enslow MS, Zollinger LV, Morton KA, et al. Comparison of 18Ffluorodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma. Clin Nucl Med 2012;37:854-61
19. Belohlávek O, Klener J, Vymazal J, et al. The diagnostics of recurrent gliomas using FDG-PET: still questionable? Nucl Med Rev Cent East Eur 2002;5:127-30 (Pubitemid 36054672)
20. Spence AM, Muzi M, Link JM, et al. NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3′-deoxy-3′-[18F] fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies. Mol Imaging Biol 2009;11:343-55
21. Janus TJ, Kim EE, Tilbury R, et al. Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol 1993;33:540-48 (Pubitemid 23143040)
22. Kim YH, Oh SW, Lim YJ, et al. Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG-PET, 11C-methionine PET and perfusion MRI. Clin Neurol Neurosurg 2010;112:758-65
23. Cai L, Gao S, Li DC, et al. Value of 18F-FDG and 11C-MET PET-CT in differentiation of brain ringlike-enhanced neoplastic and nonneoplastic lesions on MRI imaging [in Chinese]. Zhonghua Zhong Liu Za Zhi 2009;31:134-38
24. Tripathi M, Sharma R, Varshney R, et al. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors. Clin Nucl Med 2012;37:158-63
25. Li DL, Xu YK, Wang QS, et al. 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas. Chin Med J (Engl) 2012;125:91-96
26. Ye C, Pan M, Li Y, et al. 11C-MET PET/CT in the detection of recurrent cerebral glioma. [in Chinese] Chin J Stereotact Funct Neurosurg 2009;22:229-31
27. Hustinx R, Smith RJ, Benard F, et al. Can the standardized uptake value characterize primary brain tumors on FDG-PET? Eur J Nucl Med 1999;26:1501-09 (Pubitemid 29515616)
28. Jager PL, Vaalburg W, Pruim J, et al. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001;42:432-45 (Pubitemid 32207394)
29. Chung JK, Kim YK, Kim SK, et al. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG-PET. Eur J Nucl Med Mol Imaging 2002;29:176-82 (Pubitemid 44763148)
30. Nakajima T, Kumabe T, Kanamori M, et al. Differential diagnosis between radiation necrosis and glioma progression using sequential proton magnetic resonance spectroscopy and methionine positron emission tomography. Neurol Med Chir (Tokyo) 2009;49:394-401
31. Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR Am J Neuroradiol 2013;34:944-50
32. Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003;3:25
33. Arends LR, Hamza TH, van Houwelingen JC, et al. Bivariate random effects meta-analysis of ROC curves. Med Decis Making 2008;28:621-38
34. Reitsma JB, Glas AS, Rutjes AW, et al. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58:982-90 (Pubitemid 41316441)
35. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988;240:1285-93
36. Harbord RM, Whiting P, Sterne JA, et al. An empirical comparison of methods for meta-analysis of diagnostic accuracy showed hierarchical models are necessary. J Clin Epidemiol 2008;61:1095-103
37. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60 (Pubitemid 37088507)
38. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med 2002;21:1539-58
39. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109 (Pubitemid 47103521)
40. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005;58:882-93 (Pubitemid 41115772)
41. Terakawa Y, Tsuyuguchi N, Iwai Y, et al. Diagnostic accuracy of 11Cmethionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 2008;49:694-99 (Pubitemid 351717532)
42. Galldiks N, Kracht LW, Berthold F, et al. [11C]-L-methionine positron emission tomography in the management of children and young adults with brain tumors. J Neurooncol 2010;96:231-39
43. Sonoda Y, Kumabe T, Takahashi T, et al. Clinical usefulness of 11CMETPET and 201T1 SPECT for differentiation of recurrent glioma from radiation necrosis. Neurol Med Chir (Tokyo) 1998;38:342- 47, discussion 347-48
44. Tsuyuguchi N, Takami T, Sunada I, et al. Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery-in malignant glioma. Ann Nucl Med 2004;18:291-96 (Pubitemid 39100096)
45. Chen W. Clinical applications of PET in brain tumors. J Nucl Med 2007;48:1468-81 (Pubitemid 47397397)
46. Schiepers C, Chen W, Cloughesy T, et al. 18F-FDOPA kinetics in brain tumors. J Nucl Med 2007;48:1651-61
47. Floeth FW, Pauleit D, Sabel M, et al. Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med 2007;48:519-27 (Pubitemid 47571405)
48. Dunet V, Rossier C, Buck A, et al. Performance of 18F-fluoro- ethyltyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis. J Nucl Med 2012;53:207-14
49. Ozsunar Y, Mullins ME, Kwong K, et al. Glioma recurrence versus radiation necrosis? A pilot comparison of arterial spin-labeled, dynamic susceptibility contrast enhanced MRI, and FDG-PET imaging. Acad Radiol 2010;17:282-90
50. Kosaka N, Tsuchida T, Uematsu H, et al. 18F-FDG-PET of common enhancing malignant brain tumors. AJR Am J Roentgenol 2008;190:W365-69 (Pubitemid 351798559)